Hasil Pencarian (1)
small molecule | CAS: 1346242-81-6
In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial c…
Kategori:
Antineoplastic AgentsAntineoplastic and Immunomodulating AgentsCytochrome P-450 CYP2C9 Substrates
+25
Target Protein:
Fibroblast growth factor receptor 1Fibroblast growth factor receptor 2Fibroblast growth factor receptor 3
+7
Waktu ParuhThe mean effective …
Vol. DistribusiThe mean apparent v…
KlirensThe mean total appa…
Genetik
-